Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 9.89 is in line with its 1-year average of 9.20, around the middle of its 1-year range (6.34–11.75).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 9.89.
QUICK RATIO (ACID-TEST)
9.89
QUICK RATIO (ACID-TEST) AVG TTM
N/A
QUICK RATIO (ACID-TEST) AVG 3Y
N/A
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.99
median of 592 covered companies
CURRENT VS SECTOR MEDIAN
+230.83%
vs the sector median at left
Eikon Therapeutics, Inc. Common Stock
Market Cap
$411.99M
Quick Ratio (Acid-Test)
9.89
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$412.27M
Quick Ratio (Acid-Test)
1.98
TTM Avg
1.95
3Y Avg
1.91
5Y Avg
2.07
Market Cap
$408.32M
Quick Ratio (Acid-Test)
8.66
TTM Avg
7.11
3Y Avg
5.24
5Y Avg
5.24
Market Cap
$407.09M
Quick Ratio (Acid-Test)
8.92
TTM Avg
6.16
3Y Avg
7.06
5Y Avg
7.06
Market Cap
$406.54M
Quick Ratio (Acid-Test)
8.13
TTM Avg
16.34
3Y Avg
21.67
5Y Avg
17.16
Market Cap
$402.01M
Quick Ratio (Acid-Test)
10.64
TTM Avg
18.70
3Y Avg
14.71
5Y Avg
15.03
Market Cap
$425.86M
Quick Ratio (Acid-Test)
3.19
TTM Avg
3.65
3Y Avg
4.66
5Y Avg
6.11
Market Cap
$432.69M
Quick Ratio (Acid-Test)
7.35
TTM Avg
8.39
3Y Avg
5.06
5Y Avg
6.73
Market Cap
$437.27M
Quick Ratio (Acid-Test)
13.99
TTM Avg
3.82
3Y Avg
4.27
5Y Avg
5.98
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $411.99M | 9.89 | N/A | N/A | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $412.27M | 1.98 | 1.95 | 1.91 | 2.07 |
| Carlsmed, Inc. (CARL)vs › | $408.32M | 8.66 | 7.11 | 5.24 | 5.24 |
| Shoulder Innovations, Inc. (SI)vs › | $407.09M | 8.92 | 6.16 | 7.06 | 7.06 |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $406.54M | 8.13 | 16.34 | 21.67 | 17.16 |
| Neurogene Inc. (NGNE)vs › | $402.01M | 10.64 | 18.70 | 14.71 | 15.03 |
| Editas Medicine, Inc. (EDIT)vs › | $425.86M | 3.19 | 3.65 | 4.66 | 6.11 |
| Capricor Therapeutics, Inc. (CAPR)vs › | $432.69M | 7.35 | 8.39 | 5.06 | 6.73 |
| Assembly Biosciences, Inc. (ASMB)vs › | $437.27M | 13.99 | 3.82 | 4.27 | 5.98 |
| MapLight Therapeutics, Inc. (MPLT)vs › | $384.04M | 16.52 | 13.61 | 8.86 | 8.86 |
Quick Ratio
9.89
Excludes inventory
Current Ratio
9.89
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 9.89 |
| 2026-03-31 | 11.75 |
| 2025-12-31 | 6.34 |
| 2025-09-30 | 8.80 |
